{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:35:12Z","timestamp":1790757312063,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11906-019-0920-4","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T01:11:04Z","timestamp":1549933864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis"],"prefix":"10.1007","volume":"21","author":[{"given":"Hillel","family":"Sternlicht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"issue":"Suppl 1","key":"920_CR1","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.2337\/dc17-S011","volume":"40","author":"Association AD","year":"2017","unstructured":"Association AD. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(Suppl 1):S64\u201374. \n                      https:\/\/doi.org\/10.2337\/dc17-S011\n                      \n                    .","journal-title":"Diabetes Care"},{"issue":"10","key":"920_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887\n                      \n                    .","journal-title":"Circulation"},{"issue":"4","key":"920_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262\u201375.e9. \n                      https:\/\/doi.org\/10.1016\/j.jash.2014.01.007\n                      \n                    .","journal-title":"J Am Soc Hypertens"},{"issue":"3","key":"920_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/jch.13229","volume":"20","author":"K Kario","year":"2018","unstructured":"Kario K, Weber M, Ferrannini E. Nocturnal hypertension in diabetes: potential target of sodium\/glucose cotransporter 2 (SGLT2) inhibition. J Clin Hypertens (Greenwich). 2018;20(3):424\u20138. \n                      https:\/\/doi.org\/10.1111\/jch.13229\n                      \n                    .","journal-title":"J Clin Hypertens (Greenwich)."},{"key":"920_CR5","doi-asserted-by":"publisher","unstructured":"\u2022 Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(5). \n                      https:\/\/doi.org\/10.1161\/JAHA.117.005686\n                      \n                     A well-done review evaluating the changes in ambulatory BP from the different SGLT2is.","DOI":"10.1161\/JAHA.117.005686"},{"issue":"7404","key":"920_CR6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427\u20130. \n                      https:\/\/doi.org\/10.1136\/bmj.326.7404.1427\n                      \n                    .","journal-title":"BMJ"},{"issue":"3","key":"920_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"\u2022 Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4(3):211\u201320. \n                      https:\/\/doi.org\/10.1016\/S2213-8587(15)00417-9\n                      \n                     The rare paper that prospectively studied the effects of SGLT2is on BP and glycemic control in a population that required improved control of both.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"920_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2337\/dc16-2724","volume":"40","author":"E Ferrannini","year":"2017","unstructured":"\u2022 Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Barsotti E, Clerico A, et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40(6):771\u20136. \n                      https:\/\/doi.org\/10.2337\/dc16-2724\n                      \n                     An improtant paper that details the potential mechanism of how ketones are generated in diabetes when SGLT2i is given.","journal-title":"Diabetes Care"},{"issue":"7","key":"920_CR9","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care. 2016;39(7):1108\u201314. \n                      https:\/\/doi.org\/10.2337\/dc16-0330\n                      \n                    .","journal-title":"Diabetes Care"},{"issue":"3","key":"920_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S2213-8587(15)00457-X","volume":"4","author":"MHA Muskiet","year":"2016","unstructured":"Muskiet MHA, van Bommel EJ, van Raalte DH. Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes. Lancet Diabetes Endocrinol. 2016;4(3):188\u20139. \n                      https:\/\/doi.org\/10.1016\/S2213-8587(15)00457-X\n                      \n                    .","journal-title":"Lancet Diabetes Endocrinol"},{"key":"920_CR11","doi-asserted-by":"publisher","unstructured":"Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC. Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc. 2018;7(4). \n                      https:\/\/doi.org\/10.1161\/JAHA.117.007046\n                      \n                    .","DOI":"10.1161\/JAHA.117.007046"},{"issue":"2","key":"920_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrneph.2016.189","volume":"13","author":"DL Cohen","year":"2017","unstructured":"Cohen DL, Townsend RR. Hypertension in 2016: blood pressure goals, variability and SGLT2 blockade in CKD. Nat Rev Nephrol. 2017;13(2):75\u20136. \n                      https:\/\/doi.org\/10.1038\/nrneph.2016.189\n                      \n                    .","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"920_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-018-0943-5","volume":"20","author":"A Briasoulis","year":"2018","unstructured":"Briasoulis A, Al Dhaybi O, Bakris GL. SGLT2 inhibitors and mechanisms of hypertension. Curr Cardiol Rep. 2018;20(1):1. \n                      https:\/\/doi.org\/10.1007\/s11886-018-0943-5\n                      \n                    .","journal-title":"Curr Cardiol Rep"},{"issue":"9","key":"920_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853\u201362. \n                      https:\/\/doi.org\/10.1111\/dom.12127\n                      \n                    .","journal-title":"Diabetes Obes Metab"},{"key":"920_CR15","unstructured":"https:\/\/www.invokanahcp.com\/prescribing-information.pdf\n                      \n                    . Accessed 18 Nov 2018."},{"issue":"9","key":"920_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1751-7176.2011.00512.x","volume":"13","author":"DA Sica","year":"2011","unstructured":"Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich). 2011;13(9):639\u201343. \n                      https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00512.x\n                      \n                    .","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9","key":"920_CR17","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1185\/03007995.2014.919907","volume":"30","author":"MR Weir","year":"2014","unstructured":"Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30(9):1759\u201368. \n                      https:\/\/doi.org\/10.1185\/03007995.2014.919907\n                      \n                    .","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"920_CR18","doi-asserted-by":"publisher","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","volume":"308","author":"Y Lytvyn","year":"2015","unstructured":"Lytvyn Y, \u0160krti\u0107 M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015;308(2):F77\u201383. \n                      https:\/\/doi.org\/10.1152\/ajprenal.00555.2014\n                      \n                    .","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"920_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","volume":"11","author":"J Jordan","year":"2017","unstructured":"Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, et al. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J Am Soc Hypertens. 2017;11(9):604\u201312. \n                      https:\/\/doi.org\/10.1016\/j.jash.2017.07.005\n                      \n                    .","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"920_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000364909","volume":"40","author":"H Yamout","year":"2014","unstructured":"Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40(1):64\u201374. \n                      https:\/\/doi.org\/10.1159\/000364909\n                      \n                    .","journal-title":"Am J Nephrol"},{"issue":"1","key":"920_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"DZI Cherney","year":"2018","unstructured":"\u2022\u2022 Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231\u201344. \n                      https:\/\/doi.org\/10.1016\/j.kint.2017.06.017\n                      \n                     This publication stratified the effects of empagliflozin on BP, HbA1c, and weight by severity of CKD, including those with advanced CKD (stage 4).","journal-title":"Kidney Int"},{"issue":"4","key":"920_CR22","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962\u201371. \n                      https:\/\/doi.org\/10.1038\/ki.2013.356\n                      \n                    .","journal-title":"Kidney Int"},{"issue":"5","key":"920_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/dom.12090","volume":"15","author":"JF Yale","year":"2013","unstructured":"Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463\u201373. \n                      https:\/\/doi.org\/10.1111\/dom.12090\n                      \n                    .","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"920_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262\u201374. \n                      https:\/\/doi.org\/10.7326\/0003-4819-159-4-201308200-00007\n                      \n                    .","journal-title":"Ann Intern Med"},{"issue":"6","key":"920_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000484633","volume":"46","author":"MJ Jardine","year":"2017","unstructured":"\u2022 Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol. 2017;46(6):462\u201372. \n                      https:\/\/doi.org\/10.1159\/000484633\n                      \n                     Present baseline data characteristics of the CREDENCE trial detailing eGFR values, the results of which will be released in 2019.","journal-title":"Am J Nephrol"},{"issue":"6","key":"920_CR26","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00125-015-3547-2","volume":"58","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, Stenl\u00f6f K, Leiter LA, Wilding JP, Blonde L, Polidori D, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58(6):1183\u20137. \n                      https:\/\/doi.org\/10.1007\/s00125-015-3547-2\n                      \n                    .","journal-title":"Diabetologia"},{"issue":"8","key":"920_CR27","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/dom.12500","volume":"17","author":"CD Sj\u00f6str\u00f6m","year":"2015","unstructured":"Sj\u00f6str\u00f6m CD, Hashemi M, Sugg J, Ptaszynska A, Johnsson E. Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels. Diabetes Obes Metab. 2015;17(8):809\u201312. \n                      https:\/\/doi.org\/10.1111\/dom.12500\n                      \n                    .","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"920_CR28","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587\u201397. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005081\n                      \n                    .","journal-title":"Circulation"},{"issue":"5","key":"920_CR29","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/ki.2014.246","volume":"86","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int. 2014;86(5):1057\u20138. \n                      https:\/\/doi.org\/10.1038\/ki.2014.246\n                      \n                    .","journal-title":"Kidney Int"},{"key":"920_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1475-2840-13-28","volume":"13","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28. \n                      https:\/\/doi.org\/10.1186\/1475-2840-13-28\n                      \n                    .","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"920_CR31","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687\u201393. \n                      https:\/\/doi.org\/10.2337\/dc15-0843\n                      \n                    .","journal-title":"Diabetes Care"},{"issue":"3","key":"920_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.celrep.2018.09.058","volume":"25","author":"S Chakraborty","year":"2018","unstructured":"\u2022\u2022 Chakraborty S, Galla S, Cheng X, Yeo JY, Mell B, Singh V, et al. Salt-responsive metabolite, \u03b2-hydroxybutyrate, attenuates hypertension. Cell Rep. 2018;25(3):677\u201389.e4. \n                      https:\/\/doi.org\/10.1016\/j.celrep.2018.09.058\n                      \n                     Using a murine model, the authors convincingly demonstrate the antihypertensive and renoprotective effects of the ketone \u03b2-hydroxybutyrate.","journal-title":"Cell Rep"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-019-0920-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T19:17:10Z","timestamp":1581448630000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-019-0920-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["920"],"URL":"https:\/\/doi.org\/10.1007\/s11906-019-0920-4","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"12 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Bakris reports grants from Janssen, Bayer, Vascular Dynamics, and NovoNordisk, and personal fees from Merck, outside the submitted work. Dr. Sternlicht declares no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"12"}}